Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thomas F Patterson

Showing results (151-160 of 204) with videos related to

Pageof 21
Sort By:
Antimicrobial Agents and Chemotherapy|January 21, 2016
The Investigational Fungal Cyp51 Inhibitor VT-1129 Demonstrates Potent In Vitro Activity against Cryptococcus neoformans and Cryptococcus gattiiShawn R Lockhart, Annette W Fothergill, Naureen Iqbal, et al.
International Journal of Radiation Oncology, Biology, Physics|August 12, 2003
Oropharyngeal candidiasis caused by non-albicans yeast in patients receiving external beam radiotherapy for head-and-neck cancerMarta C Dahiya, Spencer W Redding, Rajiv S Dahiya, et al.
The Journal of Infection|May 9, 2006
Micafungin (FK463), alone or in combination with other systemic antifungal agents, for the treatment of acute invasive aspergillosisDavid W Denning, Kieren A Marr, Wendi M Lau, et al.
Open Forum Infectious Diseases|December 8, 2021
Coronavirus Disease 2019-Associated Invasive Fungal InfectionJohn W Baddley, George R Thompson, Sharon C-A Chen, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|October 19, 2005
A randomized study of the use of fluconazole in continuous versus episodic therapy in patients with advanced HIV infection and a history of oropharyngeal candidiasis: AIDS Clinical Trials Group Study 323/Mycoses Study Group Study 40Mitchell Goldman, Gretchen A Cloud, Karen D Wade, et al.
AIDS Research and Treatment|September 13, 2012
The Changing Epidemiology of Oropharyngeal Candidiasis in Patients with HIV/AIDS in the Era of Antiretroviral TherapyPayal K Patel, Joshua E Erlandsen, William R Kirkpatrick, et al.
Antimicrobial Agents and Chemotherapy|July 11, 2018
The Fungal Cyp51 Inhibitor VT-1129 Is Efficacious in an Experimental Model of Cryptococcal MeningitisNathan P Wiederhold, Laura K Najvar, Edward P Garvey, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|January 8, 2008
Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of AmericaThomas J Walsh, Elias J Anaissie, David W Denning, et al.
Medical Mycology|June 12, 2012
Antifungal therapy and length of hospitalization in transplant patients with invasive aspergillosisJohn W Baddley, David R Andes, Kieren A Marr, et al.
Antimicrobial Agents and Chemotherapy|August 15, 2018
<i>In Vivo</i> Efficacy of VT-1129 against Experimental Cryptococcal Meningitis with the Use of a Loading Dose-Maintenance Dose Administration StrategyNathan P Wiederhold, Xin Xu, Amy Wang, et al.
Pageof 21

Showing results (151-160 of 204) with videos related to

Sort By:
Pageof 21
Antimicrobial Agents and Chemotherapy|January 21, 2016
The Investigational Fungal Cyp51 Inhibitor VT-1129 Demonstrates Potent In Vitro Activity against Cryptococcus neoformans and Cryptococcus gattiiShawn R Lockhart, Annette W Fothergill, Naureen Iqbal, et al.
International Journal of Radiation Oncology, Biology, Physics|August 12, 2003
Oropharyngeal candidiasis caused by non-albicans yeast in patients receiving external beam radiotherapy for head-and-neck cancerMarta C Dahiya, Spencer W Redding, Rajiv S Dahiya, et al.
The Journal of Infection|May 9, 2006
Micafungin (FK463), alone or in combination with other systemic antifungal agents, for the treatment of acute invasive aspergillosisDavid W Denning, Kieren A Marr, Wendi M Lau, et al.
Open Forum Infectious Diseases|December 8, 2021
Coronavirus Disease 2019-Associated Invasive Fungal InfectionJohn W Baddley, George R Thompson, Sharon C-A Chen, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|October 19, 2005
A randomized study of the use of fluconazole in continuous versus episodic therapy in patients with advanced HIV infection and a history of oropharyngeal candidiasis: AIDS Clinical Trials Group Study 323/Mycoses Study Group Study 40Mitchell Goldman, Gretchen A Cloud, Karen D Wade, et al.
AIDS Research and Treatment|September 13, 2012
The Changing Epidemiology of Oropharyngeal Candidiasis in Patients with HIV/AIDS in the Era of Antiretroviral TherapyPayal K Patel, Joshua E Erlandsen, William R Kirkpatrick, et al.
Antimicrobial Agents and Chemotherapy|July 11, 2018
The Fungal Cyp51 Inhibitor VT-1129 Is Efficacious in an Experimental Model of Cryptococcal MeningitisNathan P Wiederhold, Laura K Najvar, Edward P Garvey, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|January 8, 2008
Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of AmericaThomas J Walsh, Elias J Anaissie, David W Denning, et al.
Medical Mycology|June 12, 2012
Antifungal therapy and length of hospitalization in transplant patients with invasive aspergillosisJohn W Baddley, David R Andes, Kieren A Marr, et al.
Antimicrobial Agents and Chemotherapy|August 15, 2018
<i>In Vivo</i> Efficacy of VT-1129 against Experimental Cryptococcal Meningitis with the Use of a Loading Dose-Maintenance Dose Administration StrategyNathan P Wiederhold, Xin Xu, Amy Wang, et al.
Pageof 21